| Title: | Trisubstituted Imidazoles as Positive Modulators of Metabotropic Glutamate Receptor Subtype 5 | ||
| Patent/Patent Application Number: | US2013150347A1 | Publication date: | June 13, 2013 |
| US2013150355A1 | |||
| Priority Application: | EP 2011–193132 | Priority date: | December 13, 2011 |
| EP 2011–193133 | |||
| Inventors: | Rudolf, K.; Bischoff, D.; Dahmann, G.; Grauert, M.; Kuelzer, R.; Wellenzohn, B. | ||
| Assignee Company: | Boehringer Ingelheim International GmbH, Germany | ||
| Disease Area: | Neurological and/or psychiatric disorder | Biological Target: | Metabotropic Glutamate Receptor Subtype 5 (mGluR5) |
| Summary: | These two application claim a series of trisubstituted imidazoles that may provide treatment for a wide variety of diseases and disorders such as schizophrenia, cognitive decline, dementia, cognitive impairment, and Alzheimer’s disease. | ||
| Important Compound Classes: |  |
||
| Key Structures: |  |
||
| Recent Review Articles: | 1. Matosin N.; Newell K. A.. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2013, 37 (3), 256–268. | ||
| 2. Lindsley C. W.; Stauffer S. R.. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004–2012). Pharm. Pat. Anal. 2013, 2 (1), 93–108. | |||
| Biological Assay: | The positive modulation of mGluR5 is measured in HEK 293A cells expressing human recombinant mGluR5 and is detected with calcium based FLIPR assay. | ||
| Pharmacological Data: | Activity of positive modulator of mGluR5
|
||
The authors declare no competing financial interest.